Exhibits dual disintegrin activity by reducing the adhesive function of alpha1beta1 and alphavbeta3 integrins, with higher affinity for alpha1beta1, thereby inhibiting integrin-dependent cell adhesion (PubMed:30287364). Inhibits cell adhesion of the human glioblastoma cell line U87 and the melanoma cell line IGR39 to fibrinogen and fibronectin, but not to collagen IV or laminin (PubMed:30287364). Inhibits cell adhesion of the rat pheochromocytoma cell line PC12 to type IV collagen (PubMed:30287364). Does not exhibit any toxicity in vivo up to 100 ug/kg body weight within 24 hours in mice (PubMed:30287364). Does not affect the viability of U87, IGR-39 and PC12 cell lines at 100 uM after 24, 48 or 72 hours incubation time (PubMed:30287364). Expressed by the venom gland. May have potential for use as an anticancer agent (PubMed:30287364). Displays anti-tumoral activity by inhibiting cell adhesion of cancerogenic cell lines without exhibiting toxicity (PubMed:30287364).